Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial.
COVID-19
Inflammation
Pentoxifylline
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
20
08
2021
revised:
24
09
2021
accepted:
03
10
2021
pubmed:
20
10
2021
medline:
21
12
2021
entrez:
19
10
2021
Statut:
ppublish
Résumé
Pentoxifylline (PTX) has broad-spectrum properties such as anti-inflammatory, anticoagulant, and antiviral effects. The aim of this study was to evaluate the efficacy and safety of PTX in hospitalized patients with COVID-19. This double-blind, placebo-controlled randomized clinical trial was conducted on hospitalized patients with COVID-19. The recruited patients were randomly (1:1) assigned to the PTX group and the placebo group. The intervention group received PTX capsules at a dose of 400 mg three times a day for 10 days along with the national regimen, including interferon plus lopinavir/ritonavir and hydroxychloroquine. The primary outcome was the improvement of clinical scores. The secondary outcomes, on the other hand, were improvement in inflammatory and oxidative stress factors and hospital complications. From a total of 102 patients who met the inclusion criteria, 72 individuals completed the study and were analyzed. No significant differences were shown in demographics and baseline clinical characteristics. Clinical scores was not significant between the two groups (P = 0.31 and 0.07 for day 5 and 11, respectively). Although the mean serum levels of interleukin-6 (IL-6) and glutathione changed significantly after 5 days in the PTX group (P = 0.03 and p = 0.04), ICU admission, intubation, and hospital stay did not differ between the two groups. The results of our study did not show any superiority of PTX over placebo in improving the clinical outcomes of patients with COVID-19. Although PTX had a beneficial effect on IL-6 and showed an acceptable safety profile, it did not offer any clinical benefit for COVID-19 complications.
Identifiants
pubmed: 34666302
pii: S1567-5769(21)00863-8
doi: 10.1016/j.intimp.2021.108227
pmc: PMC8492603
pii:
doi:
Substances chimiques
Antiviral Agents
0
IL6 protein, human
0
Interleukin-6
0
Pentoxifylline
SD6QCT3TSU
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
108227Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Comput Struct Biotechnol J. 2021;19:1379-1390
pubmed: 33680348
J Clin Oncol. 2004 Jun 1;22(11):2207-13
pubmed: 15169810
Paediatr Drugs. 2010 Oct 1;12(5):301-11
pubmed: 20799759
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
FASEB J. 2013 Sep;27(9):3524-35
pubmed: 23699177
Int Immunopharmacol. 2021 Jan;90:107209
pubmed: 33278747
Vopr Virusol. 1993 Sep-Dec;38(5):230-3
pubmed: 8284924
AIDS. 2010 Jun 1;24(9):1377-80
pubmed: 20559042
Ann Hepatol. 2013 Mar-Apr;12(2):248-55
pubmed: 23396736
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
N Engl J Med. 2020 Dec 31;383(27):2598-2600
pubmed: 33264539
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Clin Pharm Ther. 2010 Jun;35(3):257-65
pubmed: 20831528
Med Sci Monit. 2003 Jun;9(6):SR29-34
pubmed: 12824965
Blood. 1991 Apr 15;77(8):1653-6
pubmed: 1707692
Front Pharmacol. 2018 Oct 17;9:1048
pubmed: 30386231
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Clin Respir J. 2021 Jul;15(7):843-846
pubmed: 33735520
Med Princ Pract. 2021;30(1):98-100
pubmed: 33049737
Immunology. 1994 Oct;83(2):262-7
pubmed: 7835945
Med Hypotheses. 2020 Nov;144:109988
pubmed: 32540603
World J Gastroenterol. 2009 Apr 7;15(13):1613-9
pubmed: 19340904
Tumori. 1996 Jan-Feb;82(1):78-80
pubmed: 8623512
Cochrane Database Syst Rev. 2014 Nov 24;(11):CD010018
pubmed: 25418278